TheraRadar
Data updated: May 26, 2026

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (potassium chloride)

Other Approved 1989-12-26

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER is indicated for the treatment of Hypokalemia; Metabolic Alkalosis.

Source: FDA Label • OTSUKA ICU MEDCL
Jump to: Indications Approvals Trials Competitors Similar Safety Patents

How POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER Works

Potassium is the principal intracellular cation of most body tissues, maintained at an intracellular concentration of approximately 150–160 mEq/L via active ion transport. It is essential for maintaining intracellular tonicity and the electrochemical gradient across cell membranes. These processes are critical for the transmission of nerve impulses, the maintenance of normal renal function, and the contraction of cardiac, skeletal, and smooth muscle.

Source: FDA Label
2
Indications
--
Phase 3 Trials
36
Years on Market

Details

Status
Discontinued
First Approved
1989-12-26
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

OTSUKA ICU MEDCL Baxter
Active Ingredient: POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER Approval History

1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
28 FDA actions from 1989 to 2024
Jun 2024 SUPPL
Label · Labeling
FDA Letter Label
Jun 2022 SUPPL
Label · Labeling
FDA Letter Label
Jun 2019 SUPPL
Label · Labeling
FDA Letter Label

What POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER Treats

2 indications

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER is approved for 2 conditions since its original approval in 1989. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypokalemia
  • Metabolic Alkalosis
Source: FDA Label

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

4

Same indication, different mechanism — what else might this patient receive?

TRIAMTERENE
AGNITIO
2019 3 indic.
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
LANNETT CO
1987 3 indic.
Unlock 2 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

KLOR-CON M10
POTASSIUM CHLORIDE
2 shared
UPSHER SMITH LABS
Shared indications:
HypokalemiaMetabolic Alkalosis
KLOR-CON M15
POTASSIUM CHLORIDE
2 shared
UPSHER SMITH LABS
Shared indications:
HypokalemiaMetabolic Alkalosis
KLOR-CON M20
POTASSIUM CHLORIDE
2 shared
UPSHER SMITH LABS
Shared indications:
HypokalemiaMetabolic Alkalosis
View all 20 similar drugs Pro
📋

Clinical Trial Registry

8 trials
Trial Sponsor ID Phase Status Title
NCT07238400 CARDAMOM 2025P001799 R01HL181150 Ph 2 recruiting Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia
NCT04316611 POTACREH APHP180577 2019-002544-24 Ph 2 withdrawn Potassium Chloride in Out-of-hospital Cardiac Arrest Due to Refractory Ventricular Fibrillation
NCT02450773 201501157 Ph 2 withdrawn Prevention of Severe Postpartum Hypertension
NCT03627130 NITRATE-CIN 18/1 Ph 2 completed The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy
NCT03483051 PULSE-AS results posted 828994 Ph 2 completed Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS)
NCT01074918 012007-080 Ph 1, Ph 2 withdrawn Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients
NCT01818583 AK-01 Ph 4 completed Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter
NCT01085071 GRIP-COMPASS GRIP-COMPASS trial Ph 4 completed Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER FDA Label Details

Indications & Usage

FDA Label (PDF)

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER is indicated for the treatment of Hypokalemia; Metabolic Alkalosis.

Track POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA020161 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.